Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...
19mon MSN
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback